nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CYP2C8—Mometasone—systemic scleroderma	0.121	0.165	CbGbCtD
Naloxone—SLCO1A2—Prednisone—systemic scleroderma	0.0966	0.131	CbGbCtD
Naloxone—ALB—Captopril—systemic scleroderma	0.0793	0.108	CbGbCtD
Naloxone—ALB—Mycophenolate mofetil—systemic scleroderma	0.0624	0.0849	CbGbCtD
Naloxone—ABCB1—Lisinopril—systemic scleroderma	0.0554	0.0754	CbGbCtD
Naloxone—ALB—Prednisone—systemic scleroderma	0.0499	0.0679	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—systemic scleroderma	0.0484	0.0659	CbGbCtD
Naloxone—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0482	0.0656	CbGbCtD
Naloxone—ABCB1—Captopril—systemic scleroderma	0.0415	0.0564	CbGbCtD
Naloxone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0326	0.0444	CbGbCtD
Naloxone—ABCB1—Prednisone—systemic scleroderma	0.0261	0.0355	CbGbCtD
Naloxone—ALB—Methotrexate—systemic scleroderma	0.025	0.0341	CbGbCtD
Naloxone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0196	0.0266	CbGbCtD
Naloxone—CYP3A4—Prednisone—systemic scleroderma	0.0156	0.0213	CbGbCtD
Naloxone—ABCB1—Methotrexate—systemic scleroderma	0.0131	0.0178	CbGbCtD
Naloxone—Cardiac fibrillation—Lisinopril—systemic scleroderma	0.00527	0.0377	CcSEcCtD
Naloxone—TLR4—tendon—systemic scleroderma	0.00305	0.141	CbGeAlD
Naloxone—Drug dependence—Prednisone—systemic scleroderma	0.00294	0.021	CcSEcCtD
Naloxone—TLR4—lung—systemic scleroderma	0.00268	0.124	CbGeAlD
Naloxone—Withdrawal syndrome—Prednisone—systemic scleroderma	0.00196	0.014	CcSEcCtD
Naloxone—CREB1—connective tissue—systemic scleroderma	0.00195	0.0902	CbGeAlD
Naloxone—Encephalopathy—Mycophenolate mofetil—systemic scleroderma	0.00188	0.0134	CcSEcCtD
Naloxone—Ventricular fibrillation—Lisinopril—systemic scleroderma	0.0018	0.0128	CcSEcCtD
Naloxone—CREB1—smooth muscle tissue—systemic scleroderma	0.00179	0.0825	CbGeAlD
Naloxone—CREB1—skin of body—systemic scleroderma	0.00176	0.0814	CbGeAlD
Naloxone—Rhinorrhoea—Lisinopril—systemic scleroderma	0.0017	0.0121	CcSEcCtD
Naloxone—Ventricular tachycardia—Mycophenolic acid—systemic scleroderma	0.00153	0.0109	CcSEcCtD
Naloxone—ESR1—blood vessel—systemic scleroderma	0.0015	0.0692	CbGeAlD
Naloxone—Nasopharyngitis—Mometasone—systemic scleroderma	0.00144	0.0103	CcSEcCtD
Naloxone—CREB1—digestive system—systemic scleroderma	0.00141	0.0651	CbGeAlD
Naloxone—Ventricular tachycardia—Lisinopril—systemic scleroderma	0.00138	0.00983	CcSEcCtD
Naloxone—Sweating—Pentoxifylline—systemic scleroderma	0.00138	0.00982	CcSEcCtD
Naloxone—Pulmonary oedema—Mycophenolic acid—systemic scleroderma	0.00136	0.00971	CcSEcCtD
Naloxone—CREB1—tendon—systemic scleroderma	0.00134	0.062	CbGeAlD
Naloxone—Cardiac arrest—Captopril—systemic scleroderma	0.00134	0.00958	CcSEcCtD
Naloxone—Pulmonary oedema—Lisinopril—systemic scleroderma	0.00122	0.00875	CcSEcCtD
Naloxone—Ventricular tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00861	CcSEcCtD
Naloxone—Injection site reaction—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00856	CcSEcCtD
Naloxone—Flushing—Pentoxifylline—systemic scleroderma	0.0012	0.00854	CcSEcCtD
Naloxone—CREB1—lung—systemic scleroderma	0.00118	0.0544	CbGeAlD
Naloxone—Tension—Pentoxifylline—systemic scleroderma	0.0011	0.00786	CcSEcCtD
Naloxone—Nervousness—Pentoxifylline—systemic scleroderma	0.00109	0.00778	CcSEcCtD
Naloxone—Pulmonary oedema—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00767	CcSEcCtD
Naloxone—Encephalopathy—Methotrexate—systemic scleroderma	0.00106	0.0076	CcSEcCtD
Naloxone—Cardiac arrest—Mycophenolic acid—systemic scleroderma	0.00105	0.00753	CcSEcCtD
Naloxone—Hyperkinesia—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00751	CcSEcCtD
Naloxone—Tremor—Pentoxifylline—systemic scleroderma	0.00105	0.0075	CcSEcCtD
Naloxone—Agitation—Pentoxifylline—systemic scleroderma	0.00103	0.00736	CcSEcCtD
Naloxone—Mediastinal disorder—Mometasone—systemic scleroderma	0.001	0.00715	CcSEcCtD
Naloxone—Nasopharyngitis—Mycophenolic acid—systemic scleroderma	0.000992	0.00708	CcSEcCtD
Naloxone—Convulsion—Pentoxifylline—systemic scleroderma	0.000971	0.00694	CcSEcCtD
Naloxone—Hallucination—Captopril—systemic scleroderma	0.000971	0.00694	CcSEcCtD
Naloxone—Hypertension—Pentoxifylline—systemic scleroderma	0.000968	0.00691	CcSEcCtD
Naloxone—Irritability—Lisinopril—systemic scleroderma	0.000953	0.00681	CcSEcCtD
Naloxone—Cardiac arrest—Lisinopril—systemic scleroderma	0.00095	0.00679	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.000948	0.00677	CcSEcCtD
Naloxone—Flushing—Captopril—systemic scleroderma	0.000906	0.00647	CcSEcCtD
Naloxone—Nasopharyngitis—Lisinopril—systemic scleroderma	0.000893	0.00638	CcSEcCtD
Naloxone—Tachycardia—Pentoxifylline—systemic scleroderma	0.000893	0.00638	CcSEcCtD
Naloxone—Skin disorder—Pentoxifylline—systemic scleroderma	0.000889	0.00635	CcSEcCtD
Naloxone—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.000884	0.00632	CcSEcCtD
Naloxone—Tension—Captopril—systemic scleroderma	0.000834	0.00595	CcSEcCtD
Naloxone—Cardiac arrest—Mycophenolate mofetil—systemic scleroderma	0.000832	0.00594	CcSEcCtD
Naloxone—Nervousness—Captopril—systemic scleroderma	0.000825	0.00589	CcSEcCtD
Naloxone—Sweating—Mycophenolic acid—systemic scleroderma	0.000819	0.00585	CcSEcCtD
Naloxone—Dyspnoea—Pentoxifylline—systemic scleroderma	0.000816	0.00583	CcSEcCtD
Naloxone—ESR1—connective tissue—systemic scleroderma	0.000769	0.0355	CbGeAlD
Naloxone—Depression—Lisinopril—systemic scleroderma	0.000768	0.00548	CcSEcCtD
Naloxone—Mediastinal disorder—Azathioprine—systemic scleroderma	0.000768	0.00548	CcSEcCtD
Naloxone—Chills—Azathioprine—systemic scleroderma	0.000764	0.00546	CcSEcCtD
Naloxone—Hallucination—Mycophenolic acid—systemic scleroderma	0.000763	0.00545	CcSEcCtD
Naloxone—Cardiac disorder—Leflunomide—systemic scleroderma	0.000746	0.00533	CcSEcCtD
Naloxone—Sweating—Lisinopril—systemic scleroderma	0.000738	0.00527	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisone—systemic scleroderma	0.000727	0.0052	CcSEcCtD
Naloxone—Mediastinal disorder—Leflunomide—systemic scleroderma	0.000725	0.00518	CcSEcCtD
Naloxone—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000723	0.00517	CcSEcCtD
Naloxone—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000723	0.00517	CcSEcCtD
Naloxone—Chills—Leflunomide—systemic scleroderma	0.000722	0.00515	CcSEcCtD
Naloxone—Hyperkinesia—Prednisone—systemic scleroderma	0.000713	0.00509	CcSEcCtD
Naloxone—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.000712	0.00509	CcSEcCtD
Naloxone—Paraesthesia—Mometasone—systemic scleroderma	0.000709	0.00506	CcSEcCtD
Naloxone—Mental disorder—Leflunomide—systemic scleroderma	0.000705	0.00503	CcSEcCtD
Naloxone—Dyspnoea—Mometasone—systemic scleroderma	0.000704	0.00503	CcSEcCtD
Naloxone—ESR1—smooth muscle tissue—systemic scleroderma	0.000703	0.0325	CbGeAlD
Naloxone—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000696	0.00497	CcSEcCtD
Naloxone—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000691	0.00494	CcSEcCtD
Naloxone—Chills—Mycophenolic acid—systemic scleroderma	0.000688	0.00492	CcSEcCtD
Naloxone—Hallucination—Lisinopril—systemic scleroderma	0.000688	0.00491	CcSEcCtD
Naloxone—Tachycardia—Captopril—systemic scleroderma	0.000677	0.00483	CcSEcCtD
Naloxone—Pain—Mometasone—systemic scleroderma	0.000675	0.00482	CcSEcCtD
Naloxone—Depression—Mycophenolate mofetil—systemic scleroderma	0.000673	0.0048	CcSEcCtD
Naloxone—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000672	0.0048	CcSEcCtD
Naloxone—Asthenia—Pentoxifylline—systemic scleroderma	0.000656	0.00469	CcSEcCtD
Naloxone—Tension—Mycophenolic acid—systemic scleroderma	0.000655	0.00468	CcSEcCtD
Naloxone—SLCO1A2—digestive system—systemic scleroderma	0.000655	0.0302	CbGeAlD
Naloxone—Nervousness—Mycophenolic acid—systemic scleroderma	0.000649	0.00463	CcSEcCtD
Naloxone—Sweating—Mycophenolate mofetil—systemic scleroderma	0.000647	0.00462	CcSEcCtD
Naloxone—Flushing—Lisinopril—systemic scleroderma	0.000641	0.00458	CcSEcCtD
Naloxone—Angiopathy—Lisinopril—systemic scleroderma	0.000627	0.00448	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000627	0.00448	CcSEcCtD
Naloxone—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000626	0.00447	CcSEcCtD
Naloxone—Tremor—Mycophenolic acid—systemic scleroderma	0.000626	0.00447	CcSEcCtD
Naloxone—Coma—Methotrexate—systemic scleroderma	0.000624	0.00446	CcSEcCtD
Naloxone—Abdominal pain—Mometasone—systemic scleroderma	0.000624	0.00446	CcSEcCtD
Naloxone—Body temperature increased—Mometasone—systemic scleroderma	0.000624	0.00446	CcSEcCtD
Naloxone—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000623	0.00445	CcSEcCtD
Naloxone—Paraesthesia—Captopril—systemic scleroderma	0.000623	0.00445	CcSEcCtD
Naloxone—Chills—Lisinopril—systemic scleroderma	0.00062	0.00443	CcSEcCtD
Naloxone—Dyspnoea—Captopril—systemic scleroderma	0.000618	0.00442	CcSEcCtD
Naloxone—Agitation—Mycophenolic acid—systemic scleroderma	0.000614	0.00438	CcSEcCtD
Naloxone—OPRM1—TCR Signaling Pathway—CD247—systemic scleroderma	0.000613	0.00592	CbGpPWpGaD
Naloxone—Pulmonary oedema—Methotrexate—systemic scleroderma	0.000608	0.00434	CcSEcCtD
Naloxone—Mental disorder—Lisinopril—systemic scleroderma	0.000605	0.00432	CcSEcCtD
Naloxone—CREB1—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000605	0.00585	CbGpPWpGaD
Naloxone—Hypertension—Leflunomide—systemic scleroderma	0.000604	0.00432	CcSEcCtD
Naloxone—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000602	0.0043	CcSEcCtD
Naloxone—ABCB1—blood vessel—systemic scleroderma	0.000592	0.0273	CbGeAlD
Naloxone—TLR4—Spinal Cord Injury—IL1B—systemic scleroderma	0.000592	0.00572	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000592	0.00423	CcSEcCtD
Naloxone—Tension—Lisinopril—systemic scleroderma	0.00059	0.00422	CcSEcCtD
Naloxone—Skin disorder—Azathioprine—systemic scleroderma	0.000588	0.0042	CcSEcCtD
Naloxone—Nervousness—Lisinopril—systemic scleroderma	0.000584	0.00417	CcSEcCtD
Naloxone—Vomiting—Pentoxifylline—systemic scleroderma	0.000582	0.00415	CcSEcCtD
Naloxone—CREB1—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00058	0.0056	CbGpPWpGaD
Naloxone—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000579	0.00559	CbGpPWpGaD
Naloxone—Convulsion—Mycophenolic acid—systemic scleroderma	0.000579	0.00413	CcSEcCtD
Naloxone—Hypertension—Mycophenolic acid—systemic scleroderma	0.000577	0.00412	CcSEcCtD
Naloxone—Asthenia—Mometasone—systemic scleroderma	0.000566	0.00405	CcSEcCtD
Naloxone—Irritability—Prednisone—systemic scleroderma	0.000566	0.00404	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000565	0.00403	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—systemic scleroderma	0.000564	0.00403	CcSEcCtD
Naloxone—Tremor—Lisinopril—systemic scleroderma	0.000564	0.00403	CcSEcCtD
Naloxone—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000562	0.00401	CcSEcCtD
Naloxone—TLR4—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000561	0.00542	CbGpPWpGaD
Naloxone—Nervous system disorder—Leflunomide—systemic scleroderma	0.00056	0.004	CcSEcCtD
Naloxone—TLR4—Spinal Cord Injury—MMP9—systemic scleroderma	0.000558	0.00539	CbGpPWpGaD
Naloxone—Tachycardia—Leflunomide—systemic scleroderma	0.000558	0.00398	CcSEcCtD
Naloxone—ESR1—digestive system—systemic scleroderma	0.000555	0.0256	CbGeAlD
Naloxone—Skin disorder—Leflunomide—systemic scleroderma	0.000555	0.00396	CcSEcCtD
Naloxone—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000552	0.00395	CcSEcCtD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000552	0.00533	CbGpPWpGaD
Naloxone—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00392	CcSEcCtD
Naloxone—Abdominal pain—Captopril—systemic scleroderma	0.000548	0.00391	CcSEcCtD
Naloxone—Body temperature increased—Captopril—systemic scleroderma	0.000548	0.00391	CcSEcCtD
Naloxone—SLCO1A2—lung—systemic scleroderma	0.000547	0.0252	CbGeAlD
Naloxone—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000546	0.0039	CcSEcCtD
Naloxone—Nausea—Pentoxifylline—systemic scleroderma	0.000543	0.00388	CcSEcCtD
Naloxone—Chills—Mycophenolate mofetil—systemic scleroderma	0.000543	0.00388	CcSEcCtD
Naloxone—ESR1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000543	0.00524	CbGpPWpGaD
Naloxone—Diarrhoea—Mometasone—systemic scleroderma	0.00054	0.00386	CcSEcCtD
Naloxone—CREB1—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.00054	0.00521	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—ITGAM—systemic scleroderma	0.000538	0.0052	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—CD247—systemic scleroderma	0.000538	0.0052	CbGpPWpGaD
Naloxone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000535	0.00382	CcSEcCtD
Naloxone—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000532	0.0038	CcSEcCtD
Naloxone—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00053	0.00379	CcSEcCtD
Naloxone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000529	0.00378	CcSEcCtD
Naloxone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000527	0.00376	CcSEcCtD
Naloxone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000522	0.00373	CcSEcCtD
Naloxone—TLR4—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000519	0.00502	CbGpPWpGaD
Naloxone—Tension—Mycophenolate mofetil—systemic scleroderma	0.000517	0.00369	CcSEcCtD
Naloxone—Paraesthesia—Leflunomide—systemic scleroderma	0.000513	0.00367	CcSEcCtD
Naloxone—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000512	0.00366	CcSEcCtD
Naloxone—CREB1—Signaling by EGFR—CSK—systemic scleroderma	0.000509	0.00492	CbGpPWpGaD
Naloxone—Dyspnoea—Leflunomide—systemic scleroderma	0.000509	0.00364	CcSEcCtD
Naloxone—CREB1—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000509	0.00491	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000509	0.00363	CcSEcCtD
Naloxone—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000508	0.00491	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000505	0.00488	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000505	0.00487	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000504	0.00487	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—TNFAIP3—systemic scleroderma	0.000504	0.00487	CbGpPWpGaD
Naloxone—Vomiting—Mometasone—systemic scleroderma	0.000502	0.00358	CcSEcCtD
Naloxone—Asthenia—Captopril—systemic scleroderma	0.000497	0.00355	CcSEcCtD
Naloxone—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000494	0.00353	CcSEcCtD
Naloxone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000493	0.00352	CcSEcCtD
Naloxone—CREB1—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000492	0.00475	CbGpPWpGaD
Naloxone—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000489	0.0035	CcSEcCtD
Naloxone—Pain—Leflunomide—systemic scleroderma	0.000489	0.00349	CcSEcCtD
Naloxone—OPRM1—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.000487	0.0047	CbGpPWpGaD
Naloxone—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000486	0.00347	CcSEcCtD
Naloxone—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000484	0.00346	CcSEcCtD
Naloxone—Tachycardia—Lisinopril—systemic scleroderma	0.000479	0.00342	CcSEcCtD
Naloxone—Body temperature increased—Azathioprine—systemic scleroderma	0.000478	0.00342	CcSEcCtD
Naloxone—Abdominal pain—Azathioprine—systemic scleroderma	0.000478	0.00342	CcSEcCtD
Naloxone—Skin disorder—Lisinopril—systemic scleroderma	0.000477	0.00341	CcSEcCtD
Naloxone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000475	0.00339	CcSEcCtD
Naloxone—Diarrhoea—Captopril—systemic scleroderma	0.000474	0.00339	CcSEcCtD
Naloxone—Irritability—Methotrexate—systemic scleroderma	0.000473	0.00338	CcSEcCtD
Naloxone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000471	0.00336	CcSEcCtD
Naloxone—Nausea—Mometasone—systemic scleroderma	0.000469	0.00335	CcSEcCtD
Naloxone—Pain—Mycophenolic acid—systemic scleroderma	0.000466	0.00333	CcSEcCtD
Naloxone—ESR1—lung—systemic scleroderma	0.000464	0.0214	CbGeAlD
Naloxone—TLR4—Spinal Cord Injury—TGFB1—systemic scleroderma	0.00046	0.00444	CbGpPWpGaD
Naloxone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000457	0.00326	CcSEcCtD
Naloxone—Depression—Prednisone—systemic scleroderma	0.000456	0.00326	CcSEcCtD
Naloxone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000455	0.00325	CcSEcCtD
Naloxone—Abdominal pain—Leflunomide—systemic scleroderma	0.000452	0.00323	CcSEcCtD
Naloxone—Body temperature increased—Leflunomide—systemic scleroderma	0.000452	0.00323	CcSEcCtD
Naloxone—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000451	0.00436	CbGpPWpGaD
Naloxone—CREB1—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000451	0.00436	CbGpPWpGaD
Naloxone—CREB1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000448	0.00433	CbGpPWpGaD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000446	0.00318	CcSEcCtD
Naloxone—Paraesthesia—Lisinopril—systemic scleroderma	0.000441	0.00315	CcSEcCtD
Naloxone—Vomiting—Captopril—systemic scleroderma	0.000441	0.00315	CcSEcCtD
Naloxone—CREB1—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000439	0.00424	CbGpPWpGaD
Naloxone—Dyspnoea—Lisinopril—systemic scleroderma	0.000438	0.00313	CcSEcCtD
Naloxone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000431	0.00308	CcSEcCtD
Naloxone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000431	0.00308	CcSEcCtD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.00043	0.00415	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000424	0.00303	CcSEcCtD
Naloxone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00301	CcSEcCtD
Naloxone—Pain—Lisinopril—systemic scleroderma	0.00042	0.003	CcSEcCtD
Naloxone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00042	0.003	CcSEcCtD
Naloxone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000418	0.00298	CcSEcCtD
Naloxone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000416	0.00297	CcSEcCtD
Naloxone—Diarrhoea—Azathioprine—systemic scleroderma	0.000414	0.00296	CcSEcCtD
Naloxone—CREB1—B Cell Activation—BLK—systemic scleroderma	0.000414	0.004	CbGpPWpGaD
Naloxone—CREB1—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000414	0.004	CbGpPWpGaD
Naloxone—Nausea—Captopril—systemic scleroderma	0.000412	0.00294	CcSEcCtD
Naloxone—Asthenia—Leflunomide—systemic scleroderma	0.00041	0.00293	CcSEcCtD
Naloxone—Hallucination—Prednisone—systemic scleroderma	0.000408	0.00292	CcSEcCtD
Naloxone—ESR1—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000396	0.00383	CbGpPWpGaD
Naloxone—ESR1—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000396	0.00382	CbGpPWpGaD
Naloxone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000391	0.00279	CcSEcCtD
Naloxone—Diarrhoea—Leflunomide—systemic scleroderma	0.000391	0.00279	CcSEcCtD
Naloxone—Abdominal pain—Lisinopril—systemic scleroderma	0.000388	0.00277	CcSEcCtD
Naloxone—Body temperature increased—Lisinopril—systemic scleroderma	0.000388	0.00277	CcSEcCtD
Naloxone—ESR1—FOXM1 transcription factor network—MMP2—systemic scleroderma	0.000388	0.00375	CbGpPWpGaD
Naloxone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000386	0.00276	CcSEcCtD
Naloxone—Vomiting—Azathioprine—systemic scleroderma	0.000385	0.00275	CcSEcCtD
Naloxone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000384	0.00274	CcSEcCtD
Naloxone—Depression—Methotrexate—systemic scleroderma	0.000381	0.00272	CcSEcCtD
Naloxone—Flushing—Prednisone—systemic scleroderma	0.000381	0.00272	CcSEcCtD
Naloxone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000373	0.00266	CcSEcCtD
Naloxone—Angiopathy—Prednisone—systemic scleroderma	0.000372	0.00266	CcSEcCtD
Naloxone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000371	0.00265	CcSEcCtD
Naloxone—ESR1—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000371	0.00358	CbGpPWpGaD
Naloxone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000368	0.00263	CcSEcCtD
Naloxone—Sweating—Methotrexate—systemic scleroderma	0.000366	0.00262	CcSEcCtD
Naloxone—OPRM1—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000364	0.00351	CbGpPWpGaD
Naloxone—Vomiting—Leflunomide—systemic scleroderma	0.000363	0.0026	CcSEcCtD
Naloxone—Mental disorder—Prednisone—systemic scleroderma	0.00036	0.00257	CcSEcCtD
Naloxone—Nausea—Azathioprine—systemic scleroderma	0.000359	0.00257	CcSEcCtD
Naloxone—CREB1—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000354	0.00341	CbGpPWpGaD
Naloxone—Asthenia—Lisinopril—systemic scleroderma	0.000352	0.00252	CcSEcCtD
Naloxone—CREB1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000349	0.00337	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—RHOB—systemic scleroderma	0.000348	0.00336	CbGpPWpGaD
Naloxone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000347	0.00248	CcSEcCtD
Naloxone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00034	0.00243	CcSEcCtD
Naloxone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00034	0.00243	CcSEcCtD
Naloxone—Nausea—Leflunomide—systemic scleroderma	0.000339	0.00242	CcSEcCtD
Naloxone—Diarrhoea—Lisinopril—systemic scleroderma	0.000336	0.0024	CcSEcCtD
Naloxone—TLR4—Immune System—CSK—systemic scleroderma	0.000333	0.00322	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000333	0.00322	CbGpPWpGaD
Naloxone—Agitation—Prednisone—systemic scleroderma	0.000328	0.00235	CcSEcCtD
Naloxone—TLR4—Immune System—IRF5—systemic scleroderma	0.000328	0.00317	CbGpPWpGaD
Naloxone—Nausea—Mycophenolic acid—systemic scleroderma	0.000324	0.00231	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—systemic scleroderma	0.000318	0.00227	CcSEcCtD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000317	0.00306	CbGpPWpGaD
Naloxone—TLR4—Immune System—IRF8—systemic scleroderma	0.000313	0.00303	CbGpPWpGaD
Naloxone—TLR4—Immune System—ITGAM—systemic scleroderma	0.000313	0.00303	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD247—systemic scleroderma	0.000313	0.00303	CbGpPWpGaD
Naloxone—Vomiting—Lisinopril—systemic scleroderma	0.000312	0.00223	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—systemic scleroderma	0.000311	0.00222	CcSEcCtD
Naloxone—CYP3A4—digestive system—systemic scleroderma	0.00031	0.0143	CbGeAlD
Naloxone—Convulsion—Prednisone—systemic scleroderma	0.00031	0.00221	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000309	0.00221	CcSEcCtD
Naloxone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000309	0.0022	CcSEcCtD
Naloxone—Hypertension—Prednisone—systemic scleroderma	0.000308	0.0022	CcSEcCtD
Naloxone—Chills—Methotrexate—systemic scleroderma	0.000308	0.0022	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000302	0.00216	CcSEcCtD
Naloxone—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000301	0.00291	CbGpPWpGaD
Naloxone—Mental disorder—Methotrexate—systemic scleroderma	0.000301	0.00215	CcSEcCtD
Naloxone—ESR1—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.000297	0.00287	CbGpPWpGaD
Naloxone—CREB1—Leptin signaling pathway—IL1B—systemic scleroderma	0.000297	0.00287	CbGpPWpGaD
Naloxone—CREB1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000296	0.00286	CbGpPWpGaD
Naloxone—CREB1—AP-1 transcription factor network—MMP9—systemic scleroderma	0.000296	0.00286	CbGpPWpGaD
Naloxone—ESR1—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000296	0.00286	CbGpPWpGaD
Naloxone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000294	0.0021	CcSEcCtD
Naloxone—TLR4—Immune System—TNFAIP3—systemic scleroderma	0.000293	0.00283	CbGpPWpGaD
Naloxone—Nausea—Lisinopril—systemic scleroderma	0.000292	0.00208	CcSEcCtD
Naloxone—TLR4—Immune System—BLK—systemic scleroderma	0.00029	0.0028	CbGpPWpGaD
Naloxone—Nervous system disorder—Prednisone—systemic scleroderma	0.000286	0.00204	CcSEcCtD
Naloxone—Tachycardia—Prednisone—systemic scleroderma	0.000285	0.00203	CcSEcCtD
Naloxone—Skin disorder—Prednisone—systemic scleroderma	0.000283	0.00202	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—systemic scleroderma	0.000282	0.00201	CcSEcCtD
Naloxone—CREB1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000275	0.00266	CbGpPWpGaD
Naloxone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000274	0.00195	CcSEcCtD
Naloxone—OPRD1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000271	0.00262	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000271	0.00262	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000267	0.00258	CbGpPWpGaD
Naloxone—Paraesthesia—Prednisone—systemic scleroderma	0.000262	0.00187	CcSEcCtD
Naloxone—Convulsion—Methotrexate—systemic scleroderma	0.000259	0.00185	CcSEcCtD
Naloxone—CREB1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000257	0.00248	CbGpPWpGaD
Naloxone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00183	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000252	0.0018	CcSEcCtD
Naloxone—CREB1—Developmental Biology—RHOB—systemic scleroderma	0.000248	0.0024	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000247	0.00238	CbGpPWpGaD
Naloxone—CREB1—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.000244	0.00236	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000242	0.00234	CbGpPWpGaD
Naloxone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000239	0.00171	CcSEcCtD
Naloxone—OPRK1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000238	0.0023	CbGpPWpGaD
Naloxone—TLR4—Immune System—CTLA4—systemic scleroderma	0.000237	0.00229	CbGpPWpGaD
Naloxone—Skin disorder—Methotrexate—systemic scleroderma	0.000237	0.00169	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000236	0.00168	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—systemic scleroderma	0.000231	0.00165	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—systemic scleroderma	0.000231	0.00165	CcSEcCtD
Naloxone—ESR1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000229	0.00221	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000223	0.00216	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00022	0.00212	CbGpPWpGaD
Naloxone—ABCB1—digestive system—systemic scleroderma	0.000219	0.0101	CbGeAlD
Naloxone—Paraesthesia—Methotrexate—systemic scleroderma	0.000219	0.00156	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—systemic scleroderma	0.000217	0.00155	CcSEcCtD
Naloxone—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000211	0.00204	CbGpPWpGaD
Naloxone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00021	0.0015	CcSEcCtD
Naloxone—Asthenia—Prednisone—systemic scleroderma	0.000209	0.00149	CcSEcCtD
Naloxone—Pain—Methotrexate—systemic scleroderma	0.000208	0.00149	CcSEcCtD
Naloxone—OPRM1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000201	0.00194	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.0002	0.00193	CbGpPWpGaD
Naloxone—Diarrhoea—Prednisone—systemic scleroderma	0.0002	0.00143	CcSEcCtD
Naloxone—CREB1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000199	0.00193	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000199	0.00193	CbGpPWpGaD
Naloxone—CREB1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000196	0.00189	CbGpPWpGaD
Naloxone—TLR4—Immune System—HLA-DQB1—systemic scleroderma	0.000196	0.00189	CbGpPWpGaD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	0.000195	0.00189	CbGpPWpGaD
Naloxone—ESR1—Leptin signaling pathway—IL1B—systemic scleroderma	0.000195	0.00188	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—MMP9—systemic scleroderma	0.000194	0.00187	CbGpPWpGaD
Naloxone—Body temperature increased—Methotrexate—systemic scleroderma	0.000193	0.00138	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—systemic scleroderma	0.000193	0.00138	CcSEcCtD
Naloxone—CREB1—Adaptive Immune System—CSK—systemic scleroderma	0.000192	0.00185	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.00019	0.00183	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000189	0.00183	CbGpPWpGaD
Naloxone—CREB1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000188	0.00182	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000188	0.00182	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD247—systemic scleroderma	0.000188	0.00181	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—ITGAM—systemic scleroderma	0.000188	0.00181	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000187	0.00181	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL1A—systemic scleroderma	0.000186	0.00179	CbGpPWpGaD
Naloxone—OPRD1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000186	0.00179	CbGpPWpGaD
Naloxone—Vomiting—Prednisone—systemic scleroderma	0.000185	0.00132	CcSEcCtD
Naloxone—TLR4—Immune System—CD40LG—systemic scleroderma	0.000185	0.00178	CbGpPWpGaD
Naloxone—ABCB1—lung—systemic scleroderma	0.000183	0.00846	CbGeAlD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000182	0.00176	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD247—systemic scleroderma	0.00018	0.00174	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.00018	0.00174	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000176	0.0017	CbGpPWpGaD
Naloxone—Asthenia—Methotrexate—systemic scleroderma	0.000175	0.00125	CcSEcCtD
Naloxone—Nausea—Prednisone—systemic scleroderma	0.000173	0.00124	CcSEcCtD
Naloxone—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000172	0.00166	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.00017	0.00164	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000169	0.00164	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000169	0.00163	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—BLK—systemic scleroderma	0.000167	0.00161	CbGpPWpGaD
Naloxone—Diarrhoea—Methotrexate—systemic scleroderma	0.000167	0.00119	CcSEcCtD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	0.000166	0.0016	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000165	0.0016	CbGpPWpGaD
Naloxone—ESR1—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000163	0.00158	CbGpPWpGaD
Naloxone—OPRK1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000163	0.00157	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00016	0.00154	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.00016	0.00154	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00016	0.00154	CbGpPWpGaD
Naloxone—Vomiting—Methotrexate—systemic scleroderma	0.000155	0.00111	CcSEcCtD
Naloxone—OPRD1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000153	0.00148	CbGpPWpGaD
Naloxone—CREB1—Disease—SMAD7—systemic scleroderma	0.000152	0.00147	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—TGFB1—systemic scleroderma	0.000149	0.00144	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000147	0.00142	CbGpPWpGaD
Naloxone—Nausea—Methotrexate—systemic scleroderma	0.000145	0.00103	CcSEcCtD
Naloxone—CREB1—Signaling by GPCR—RHOB—systemic scleroderma	0.00014	0.00135	CbGpPWpGaD
Naloxone—CREB1—Disease—TGFBI—systemic scleroderma	0.000139	0.00135	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—RHOB—systemic scleroderma	0.000139	0.00135	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—EDN1—systemic scleroderma	0.000139	0.00134	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000138	0.00133	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CTLA4—systemic scleroderma	0.000137	0.00132	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000136	0.00132	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000135	0.0013	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000135	0.0013	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL1B—systemic scleroderma	0.00013	0.00126	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000128	0.00124	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000124	0.0012	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000123	0.00119	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—RHOB—systemic scleroderma	0.000122	0.00118	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—EDN1—systemic scleroderma	0.000122	0.00117	CbGpPWpGaD
Naloxone—CREB1—Immune System—CSK—systemic scleroderma	0.000116	0.00112	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP2—systemic scleroderma	0.000116	0.00112	CbGpPWpGaD
Naloxone—CREB1—Immune System—IRF5—systemic scleroderma	0.000114	0.00111	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000114	0.0011	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000113	0.00109	CbGpPWpGaD
Naloxone—CREB1—Disease—HSPG2—systemic scleroderma	0.000111	0.00107	CbGpPWpGaD
Naloxone—CREB1—Immune System—IRF8—systemic scleroderma	0.000109	0.00106	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD247—systemic scleroderma	0.000109	0.00106	CbGpPWpGaD
Naloxone—CREB1—Immune System—ITGAM—systemic scleroderma	0.000109	0.00106	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000109	0.00106	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000109	0.00105	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—SMAD7—systemic scleroderma	0.000108	0.00104	CbGpPWpGaD
Naloxone—CREB1—Disease—CSK—systemic scleroderma	0.000107	0.00104	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SMAD7—systemic scleroderma	0.000107	0.00103	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SMAD7—systemic scleroderma	0.000106	0.00103	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD40LG—systemic scleroderma	0.000106	0.00103	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000103	0.000998	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RHOB—systemic scleroderma	0.000103	0.000997	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SELP—systemic scleroderma	0.000103	0.000997	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—EDN1—systemic scleroderma	0.000103	0.000992	CbGpPWpGaD
Naloxone—CREB1—Immune System—TNFAIP3—systemic scleroderma	0.000102	0.000989	CbGpPWpGaD
Naloxone—CREB1—Immune System—BLK—systemic scleroderma	0.000101	0.000977	CbGpPWpGaD
Naloxone—CREB1—Disease—CD247—systemic scleroderma	0.000101	0.000975	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—TNFSF13—systemic scleroderma	0.0001	0.000966	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	9.87e-05	0.000954	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL1B—systemic scleroderma	9.69e-05	0.000935	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RHOB—systemic scleroderma	9.63e-05	0.000931	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CCL2—systemic scleroderma	9.48e-05	0.000915	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SMAD7—systemic scleroderma	9.33e-05	0.000901	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	9.22e-05	0.000891	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CSK—systemic scleroderma	8.78e-05	0.000848	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP9—systemic scleroderma	8.69e-05	0.000839	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—TGFB1—systemic scleroderma	8.67e-05	0.000837	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.32e-05	0.000803	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CCL2—systemic scleroderma	8.31e-05	0.000803	CbGpPWpGaD
Naloxone—CREB1—Immune System—CTLA4—systemic scleroderma	8.29e-05	0.000801	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.27e-05	0.000799	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RHOB—systemic scleroderma	8.26e-05	0.000798	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	8.26e-05	0.000798	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ITGAM—systemic scleroderma	8.25e-05	0.000797	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP2—systemic scleroderma	8.25e-05	0.000796	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RHOB—systemic scleroderma	8.23e-05	0.000795	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SMAD7—systemic scleroderma	7.89e-05	0.000762	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—EDN1—systemic scleroderma	7.84e-05	0.000757	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HSPG2—systemic scleroderma	7.79e-05	0.000752	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HSPG2—systemic scleroderma	7.76e-05	0.00075	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	7.67e-05	0.000741	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	7.54e-05	0.000728	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CSK—systemic scleroderma	7.52e-05	0.000726	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CSK—systemic scleroderma	7.5e-05	0.000724	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RHOB—systemic scleroderma	7.22e-05	0.000697	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	7.16e-05	0.000691	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EDN1—systemic scleroderma	7.14e-05	0.000689	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EDN1—systemic scleroderma	7.12e-05	0.000687	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CCL2—systemic scleroderma	7.02e-05	0.000678	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SMAD7—systemic scleroderma	6.99e-05	0.000675	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—EDN1—systemic scleroderma	6.87e-05	0.000664	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-DQB1—systemic scleroderma	6.83e-05	0.000659	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HSPG2—systemic scleroderma	6.81e-05	0.000657	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CSK—systemic scleroderma	6.57e-05	0.000635	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1A—systemic scleroderma	6.48e-05	0.000626	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD40LG—systemic scleroderma	6.45e-05	0.000623	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.3e-05	0.000609	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.27e-05	0.000605	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EDN1—systemic scleroderma	6.24e-05	0.000603	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP9—systemic scleroderma	6.2e-05	0.000599	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RHOB—systemic scleroderma	6.1e-05	0.000589	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CTGF—systemic scleroderma	5.95e-05	0.000574	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—EDN1—systemic scleroderma	5.81e-05	0.000561	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HSPG2—systemic scleroderma	5.75e-05	0.000556	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CTGF—systemic scleroderma	5.71e-05	0.000552	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CSK—systemic scleroderma	5.56e-05	0.000537	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RHOB—systemic scleroderma	5.41e-05	0.000522	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EDN1—systemic scleroderma	5.27e-05	0.000509	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TGFB1—systemic scleroderma	5.11e-05	0.000493	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HSPG2—systemic scleroderma	5.1e-05	0.000493	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CSK—systemic scleroderma	4.93e-05	0.000476	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CCL2—systemic scleroderma	4.88e-05	0.000471	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CCL2—systemic scleroderma	4.86e-05	0.00047	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCL2—systemic scleroderma	4.26e-05	0.000412	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EDN1—systemic scleroderma	4.22e-05	0.000407	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EDN1—systemic scleroderma	4.2e-05	0.000406	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MMP1—systemic scleroderma	4.13e-05	0.000399	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.84e-05	0.000371	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.79e-05	0.000366	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HSPG2—systemic scleroderma	3.7e-05	0.000358	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EDN1—systemic scleroderma	3.69e-05	0.000356	CbGpPWpGaD
Naloxone—ALB—Metabolism—HSPG2—systemic scleroderma	3.68e-05	0.000356	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS3—systemic scleroderma	3.67e-05	0.000354	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL2—systemic scleroderma	3.6e-05	0.000348	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1B—systemic scleroderma	3.38e-05	0.000327	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.23e-05	0.000312	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EDN1—systemic scleroderma	3.11e-05	0.000301	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS3—systemic scleroderma	3e-05	0.000289	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL2—systemic scleroderma	2.88e-05	0.000278	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL2—systemic scleroderma	2.87e-05	0.000277	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CTGF—systemic scleroderma	2.81e-05	0.000271	CbGpPWpGaD
Naloxone—ALB—Metabolism—CTGF—systemic scleroderma	2.79e-05	0.00027	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EDN1—systemic scleroderma	2.76e-05	0.000267	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOS3—systemic scleroderma	2.57e-05	0.000248	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOS3—systemic scleroderma	2.56e-05	0.000247	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL2—systemic scleroderma	2.52e-05	0.000243	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—systemic scleroderma	2.49e-05	0.00024	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CTGF—systemic scleroderma	2.45e-05	0.000236	CbGpPWpGaD
Naloxone—CREB1—Disease—TGFB1—systemic scleroderma	2.43e-05	0.000234	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—systemic scleroderma	2.25e-05	0.000217	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL2—systemic scleroderma	2.13e-05	0.000206	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—systemic scleroderma	2.06e-05	0.000199	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—systemic scleroderma	2.05e-05	0.000198	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.99e-05	0.000192	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—systemic scleroderma	1.98e-05	0.000191	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—systemic scleroderma	1.9e-05	0.000183	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL2—systemic scleroderma	1.89e-05	0.000182	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—systemic scleroderma	1.8e-05	0.000174	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFB1—systemic scleroderma	1.7e-05	0.000164	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—systemic scleroderma	1.69e-05	0.000164	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—systemic scleroderma	1.68e-05	0.000163	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—systemic scleroderma	1.52e-05	0.000147	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.51e-05	0.000146	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—systemic scleroderma	1.48e-05	0.000143	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—systemic scleroderma	1.35e-05	0.00013	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—systemic scleroderma	1.25e-05	0.000121	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.22e-05	0.000118	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—systemic scleroderma	1.22e-05	0.000117	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—systemic scleroderma	1.11e-05	0.000107	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—systemic scleroderma	1.06e-05	0.000103	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.56e-06	6.34e-05	CbGpPWpGaD
